%0 Journal Article %A MOON HEE YANG %A KYU TAEK LEE %A SERA YANG %A JONG KYOON LEE %A KWANG HYUCK LEE %A JONG CHUL RHEE %T KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells %D 2015 %J Anticancer Research %P 183-189 %V 35 %N 1 %X Background/Aim: Gemcitabine is a drug commonly used to treat pancreatic cancer but chemoresistance to it is a common clinical issue. KML001 (sodium meta-arsenite) has demonstrated certain antitumor activity. The objective of the study was to evaluate the influence of KML001 on the anticancer activity of gemcitabine against pancreatic cancer cells. Materials and Methods: Cell proliferation, migration, and invasion were assessed, as well as the expression of nuclear factor-kappa B (NF-κB) p65, epidermal growth factor receptor (EGFR), matrix metalloproteinase-2 (MMP2), and vascular endothelial growth factor-C (VEGFC) in pancreatic cancer cells. Results: Treatment with a combination of KML001 and gemcitabine resulted in significant inhibition of cell proliferation, migration, and invasion, and significantly reduced EGFR and MMP2 expression compared to gemcitabine treatment-alone. Conclusion: Combination treatment of gemcitabine and KML001 could be an effective chemotherapeutic treatment for pancreatic cancer. %U https://ar.iiarjournals.org/content/anticanres/35/1/183.full.pdf